We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna Corporation (CI - Free Report) is set to report second-quarter 2021 results on Aug 5, before the opening bell.
Q2 Estimates
The Zacks Consensus Estimate for the company’s earnings is pegged at $4.96 per share, indicating a decline of 14.63% from the year-ago quarter’s reported figure.
The consensus mark for revenues stands at $41.27 billion, implying a rise of 5.26% from the prior-year quarter’s reported number.
Factors to Note
Strong performances across the company’s Evernorth, U.S. Medical and International Markets businesses are likely to have contributed to its to-be-reported quarter’s revenues.
Delving deeper into the company’s segments, the Evernorth unit, which was rebranded in September 2020, might have gained momentum from a growing customer base and higher pharmacy scripts volumes in the to-be-reported quarter. Revenues are likely to have been driven by the insourcing of U.S. Medical pharmacy volumes and strong organic growth including a rise in retail network and specialty pharmacy services.
Its U.S. Government business is likely to have gained from customer growth by continuing to expand its addressable markets.
The U.S. Medical business is likely to have benefited from customer growth across the company’s Select segment and Medicare Advantage business, and a rise in premiums and return of the health insurance tax.
The International Markets business revenues are likely to have shown consistent business growth. Operating earnings might have been weighed on by costs incurred to support customers and employees, and investments made in the business for growth.
Numerous cost-curbing initiatives might have offset the company’s selling, general and administration expenses to some extent in the to-be-reported quarter.
Earnings Surprise History
The company boasts an encouraging earnings surprise track. Its bottom line surpassed estimates in three of the trailing four quarters (missed the mark in one), the average surprise being 5.43%. This is depicted in the chart below:
Our proven model does not predict an earnings beat for Cigna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here.
Earnings ESP: Cigna has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate of $4.96 is in line with the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Among other health insurers that have reported second-quarter results so far, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem Inc. beat the respective estimates by 6.6%, 0.44% and 10.88%, respectively.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What's in Store for Cigna's (CI) Earnings in Q2?
Cigna Corporation (CI - Free Report) is set to report second-quarter 2021 results on Aug 5, before the opening bell.
Q2 Estimates
The Zacks Consensus Estimate for the company’s earnings is pegged at $4.96 per share, indicating a decline of 14.63% from the year-ago quarter’s reported figure.
The consensus mark for revenues stands at $41.27 billion, implying a rise of 5.26% from the prior-year quarter’s reported number.
Factors to Note
Strong performances across the company’s Evernorth, U.S. Medical and International Markets businesses are likely to have contributed to its to-be-reported quarter’s revenues.
Delving deeper into the company’s segments, the Evernorth unit, which was rebranded in September 2020, might have gained momentum from a growing customer base and higher pharmacy scripts volumes in the to-be-reported quarter. Revenues are likely to have been driven by the insourcing of U.S. Medical pharmacy volumes and strong organic growth including a rise in retail network and specialty pharmacy services.
Its U.S. Government business is likely to have gained from customer growth by continuing to expand its addressable markets.
The U.S. Medical business is likely to have benefited from customer growth across the company’s Select segment and Medicare Advantage business, and a rise in premiums and return of the health insurance tax.
The International Markets business revenues are likely to have shown consistent business growth. Operating earnings might have been weighed on by costs incurred to support customers and employees, and investments made in the business for growth.
Numerous cost-curbing initiatives might have offset the company’s selling, general and administration expenses to some extent in the to-be-reported quarter.
Earnings Surprise History
The company boasts an encouraging earnings surprise track. Its bottom line surpassed estimates in three of the trailing four quarters (missed the mark in one), the average surprise being 5.43%. This is depicted in the chart below:
Cigna Corporation Price and EPS Surprise
Cigna Corporation price-eps-surprise | Cigna Corporation Quote
What Our Quantitative Model Predicts
Our proven model does not predict an earnings beat for Cigna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here.
Earnings ESP: Cigna has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate of $4.96 is in line with the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cigna currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Among other health insurers that have reported second-quarter results so far, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem Inc. beat the respective estimates by 6.6%, 0.44% and 10.88%, respectively.